Abiomed shares attractive after pullback, says Stephens


After Abiomed's stock fell due to uncertainty stemming from the ICD-10 reimbursement coding process, Stephens does not expect the process to undermine the company's revenue growth over the long-term. The firm thinks the stock's decline creates an attractive entry point for more value-conscious investors and it keeps a Buy rating on the shares.

View Comments